Presigna turns public evidence, meeting context, and next actions into one connected BD workflow so biotech teams can focus on the opportunities most likely to matter.
GLP-1 / muscle preservation · Profile v2
Phase 3 topline reported for an oral metabolic candidate.
New trial registration in an adjacent indication.
Biotech BD teams lose momentum when partner discovery, meeting preparation, and follow-up live in separate files and personal notes.
The shortlist starts from familiar names, while less obvious but relevant companies remain undiscovered.
The ask, the objection, and the next action are scattered across notebooks, inboxes, and slide decks.
Teams spend time on low-probability deals because there is no shared evidence base for what to pursue next.
Presigna connects discovery, preparation, and follow-up without forcing your team to rebuild its process.
Start with public information already prefilled. Correct what is wrong and add the rights, stage, and timeline only your team knows.
→ A shared source of truthSee where each company fits, where constraints exist, and where public evidence is insufficient, factor by factor.
→ A defensible priority listRequest a target brief before the meeting, then keep the ask, agreement, and next action attached to the same company and asset.
→ A deal history the team can useFour focused tools work together around the same asset, company, and deal context.
Compare your asset against companies factor by factor. Every conclusion is linked to the reasoning, profile version, cut-off date, and source.
Relevant mechanism and stated portfolio interest.
Active cardiometabolic franchise and recent deal activity.
Portfolio currently favors later-stage opportunities.
Public expansion strategy aligns with available rights.
No current public statement. Requires direct validation.
Confirmed attendee at the selected partnering event.
Keep confirmed company facts separate from what those facts mean for your specific asset.
Reviewed signals stay linked to the original filing, trial registry, release, or paper.
Phase 3 topline reported for an oral metabolic candidate.
Mechanism paper cited by two companies on your watchlist.
Turn meeting notes into a structured history without losing the original note or your edits.
Asked: muscle glucose-uptake data after CDA. Next: return CDA draft.
Asked: which indication is the first priority.
See the partners you may be missing, the evidence behind each judgment, and the next actions already waiting for your team.